Albutoin
Anticonvulsant compound
 | |
| Clinical data | |
|---|---|
| Other names | BAX-422Z[1] |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| ChemSpider |
|
| UNII |
|
| Chemical and physical data | |
| Formula | C10H16N2OS |
| Molar mass | 212.31 g·mol−1 |
| 3D model (JSmol) |
|
| |
Albutoin is an anticonvulsant.[1][2] It was marketed in Europe as CO-ORD and Euprax by Baxter Laboratories.[1] It was evaluated by the United States Food and Drug Administration, but not approved.[3]
References
- ^ a b c Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 24–. ISBN 978-1-4757-2085-3.
- ^ Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, Fisher P, Ellenberg J (April 1974). "Evaluation of albutoin as an antiepileptic drug". Clinical Pharmacology and Therapeutics. 15 (4): 406–16. doi:10.1002/cpt1974154406. PMID 4206927. S2CID 41909514.
- ^ Shorvon SD (March 2009). "Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009". Epilepsia. 50 (Suppl 3): 93–130. doi:10.1111/j.1528-1167.2009.02042.x. PMID 19298435.
- v
- t
- e
Anticonvulsants (N03)
| GABAAR PAMs |
|
|---|---|
| GABA-T inhibitors |
|
| Others |
modulators
| CA inhibitors |
|
|---|---|
| Others |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
